<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs001009.v1.p1" parentStudy="phs001009.v1.p1" createDate="2015-10-22" modDate="2016-04-05">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Mario Castro, MD</td><td>Washington University School of Medicine, St. Louis, MO, USA</td></tr>
		<tr><td>Co-Principal Investigator</td><td>Leonard Bacharier, MD</td><td>Washington University School of Medicine, St. Louis, MO, USA</td></tr>
		<tr><td>Funding Source</td><td>HL 61895</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Determinants of Asthma Following RSV Bronchiolitis in Early Life</StudyNameEntrez>
	<StudyNameReportPage>Determinants of Asthma Following RSV Bronchiolitis in Early Life</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Prospective</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>The goal of the RSV Bronchiolitis in Early Life (RBEL) study is to determine how specific genetic, biologic, and immunologic characteristics interact to predispose individuals to develop asthma. Participants were carefully recruited by selecting a prospective cohort of 206 infants with severe respiratory syncytial virus (RSV) bronchiolitis who were at substantial risk of developing asthma.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Infants 12 months of age or younger were <b>included</b> in the RBEL study if they had severe bronchiolitis requiring emergency department care or hospitalization, a positive nasopharyngeal swab confirming RSV infection, and physician-documented wheezing during acute illness. <b>Exclusion</b> criteria included a history of previous wheezing and/or diagnosis of asthma, congenital abnormalities of the heart and lung, cystic fibrosis diagnosed in the patient or immediate family, regular use of anti-gastroesophageal reflux medication, bronchodilators, or anti-inflammatory medications. </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Pubmed pmid="26587832"/>
		</Publication>
		<Publication>
			<Pubmed pmid="22444510"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Asthma"/>
		<Disease vocab_source="MESH" vocab_term="Bronchiolitis, Viral"/>
		<Disease vocab_source="MESH" vocab_term="Respiratory Syncytial Virus, Human"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Mario Castro, MD</AttName>
			<Institution>Washington University School of Medicine, St. Louis, MO, USA</Institution>
		</Header>
		<Header title="Co-Principal Investigator">
			<AttName>Leonard Bacharier, MD</AttName>
			<Institution>Washington University School of Medicine, St. Louis, MO, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>HL 61895</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="0" shortName="NRUP" longName="Subjects did not participate in the study, did not complete a consent document and are included only for the pedigree structure and/or genotype controls, such as HapMap subjects"/>
		<ConsentGroup groupNum="2" shortName="DS-AAR-IRB" longName="Disease-Specific (Allergy, Asthma, and Respiratory, IRB)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs001009.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001009.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs001009.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="2">
        <ConsentName>Disease-Specific (Allergy, Asthma, and Respiratory, IRB)</ConsentName>
        <ConsentAbbrev>DS-AAR-IRB</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Allergy, Asthma, and Respiratory.
Requestor must provide documentation of local IRB approval.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
